Hoang Thanh Chi1, Bui Thi Kim Ly2, Hoang Anh Vu3, Yuko Sato4, Phu Chi Dung1, Phan Thi Xinh5. 1. Department of Molecular Cytogenetics, Hematology and Blood Transfusion Hospital in Ho Chi Minh City, Ho Chi Minh, Vietnam. 2. Department of Medical Genome Sciences, Graduate School of Frontier Sciences, the University of Tokyo, Tokyo, Japan. 3. Center for Molecular Biomedicine, The University of Medicine and Pharmacy-Ho Chi Minh City, Ho Chi Minh, Vietnam. 4. Basic nursing science, The Japanese Red Cross College of Nursing Japan, Tokyo, Japan. 5. Department of Molecular Cytogenetics, Hematology and Blood Transfusion Hospital in Ho Chi Minh City, Ho Chi Minh, Vietnam ; Center for Molecular Biomedicine, The University of Medicine and Pharmacy-Ho Chi Minh City, Ho Chi Minh, Vietnam.
Abstract
OBJECTIVE: To investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. METHODS: Cell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western blot analysis were performed to test the protein expression of NPM1, AKT, those associated with apoptosis. RESULTS: EGCG can down-regulate the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Moreover, EGCG also suppressed the cell proliferation and induced apoptosis in IMS-M2 cells. CONCLUSIONS: The results suggested that EGCG could be considered as a reagent for treatment of AML patients with NPM1 mutations.
OBJECTIVE: To investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. METHODS: Cell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western blot analysis were performed to test the protein expression of NPM1, AKT, those associated with apoptosis. RESULTS:EGCG can down-regulate the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Moreover, EGCG also suppressed the cell proliferation and induced apoptosis in IMS-M2 cells. CONCLUSIONS: The results suggested that EGCG could be considered as a reagent for treatment of AMLpatients with NPM1 mutations.
Authors: Karen S Rees-Unwin; Robin Faragher; Richard D Unwin; Julie Adams; Philip J Brown; Ann-Marie Buckle; Andrew Pettitt; Claire V Hutchinson; Suzanne M Johnson; Karen Pulford; Alison H Banham; Anthony D Whetton; Guy Lucas; David Y Mason; John Burthem Journal: Br J Haematol Date: 2009-11-23 Impact factor: 6.998
Authors: H Quentmeier; M P Martelli; W G Dirks; N Bolli; A Liso; R A F Macleod; I Nicoletti; R Mannucci; A Pucciarini; B Bigerna; M F Martelli; C Mecucci; H G Drexler; B Falini Journal: Leukemia Date: 2005-10 Impact factor: 11.528
Authors: Anne S Tsao; Diane Liu; Jack Martin; Xi-ming Tang; J Jack Lee; Adel K El-Naggar; Ignacio Wistuba; Kirk S Culotta; Li Mao; Ann Gillenwater; Yuko M Sagesaka; Waun K Hong; Vassiliki Papadimitrakopoulou Journal: Cancer Prev Res (Phila) Date: 2009-11
Authors: Roberta Ranieri; Giulia Pianigiani; Sofia Sciabolacci; Vincenzo Maria Perriello; Andrea Marra; Valeria Cardinali; Sara Pierangeli; Francesca Milano; Ilaria Gionfriddo; Lorenzo Brunetti; Maria Paola Martelli; Brunangelo Falini Journal: Leukemia Date: 2022-08-25 Impact factor: 12.883